The European Medicines Agency (EMA) has started the evaluation of the Russian corona vaccine Sputnik V. If the evaluation is positive, a formal application for approval can be submitted.
The so-called ‘rolling review’ is the last step before a formal approval request can be submitted. By starting the evaluation, it should take less time than normal to assess a possible market application.
9 out of 10 vaccinees are protected
According to the vaccine designers at the Russian institute Gamaleya, the Russian corona vaccine Sputnik V would protect nine out of ten vaccinees against Covid-19. They rely on an interim analysis of an experimental round of vaccination among tens of thousands of volunteers. As with the majority of the other vaccines, two injections must be made to enjoy optimal protection.
Russia has already announced that it will be able to deliver enough doses from June to vaccinate 50 million Europeans against the virus. Of course, the approval of Europe must come first. In addition, Russia expects several European countries to approve the vaccine this month, independently of the EMA.
Three approved vaccines in the EU
Currently, three vaccines have already been approved by Europe: Pfizer / BioNTech, Moderna and Oxford / AstraZeneca. On March 11, the EMA will pronounce on the Johnson & Johnson vaccine. There are also rolling reviews for the vaccines from Novavax and CureVac.
Also read: Putin pumped an immense amount of money into scientific research. Do we see the result with Sputnik V?